Valuation: Conavi Medical Corp.

Market Cap 22.77M 16.25M 14.2M 13.11M 12.08M 1.57B 23.27M 157M 61.61M 766M 61.03M 59.69M 2.64B P/E 2024 *
-
P/E 2025 -1.88x
Enterprise Value 36.83M 26.29M 22.98M 21.2M 19.54M 2.53B 37.65M 253M 99.67M 1.24B 98.73M 96.57M 4.27B EV / Sales 2024 *
-
EV / Sales 2025 7.18x
Free-Float
66.52%
Yield 2024 *
-
Yield 2025 -
1 day+0.71%
1 week-6.90%
Current month-4.19%
1 month-6.51%
3 months-50.92%
6 months-49.06%
Current year-52.22%
1 week 0.15
Extreme 0.15
0.18
1 month 0.15
Extreme 0.1457
0.18
Current year 0.15
Extreme 0.1457
0.43
1 year 0.15
Extreme 0.1457
0.56
3 years 0
Extreme 0.0007
1
5 years 0
Extreme 0.0007
1
10 years 0
Extreme 0.0007
1
Change 5-day change 1-year change 3-year change Capi.($)
+0.71%-6.90% - - 16.25M
-1.97%+1.03%+28.39%+1.68% 198B
-0.58%+2.40%+7.25%-15.35% 144B
-14.15%-15.08%-33.40%-2.68% 122B
-1.32%-1.65%-57.52%-16.63% 65.44B
-2.40%-7.03%+12.08%-6.81% 49.36B
-0.11%+1.53%-23.83%-30.51% 44.75B
-3.41%-2.11%+15.33%+9.95% 37.13B
-2.44%-1.98%+28.33%+35.71% 36.23B
-4.00%-2.52%-16.97%-23.52% 28.69B
Average -2.97%-2.30%-4.48%-5.35% 80.68B
Weighted average by Cap. -3.78%-1.83%-0.76%-5.52%

Financials

2024 2025
Net sales 2.16M 1.54M 1.35M 1.24M 1.15M 149M 2.21M 14.87M 5.85M 72.75M 5.79M 5.67M 250M 9.12M 6.51M 5.69M 5.25M 4.84M 627M 9.32M 62.76M 24.68M 307M 24.45M 23.92M 1.06B
Net income -43.62M -31.13M -27.21M -25.1M -23.14M -3B -44.58M -300M -118M -1.47B -117M -114M -5.05B -20.52M -14.64M -12.8M -11.81M -10.88M -1.41B -20.97M -141M -55.52M -691M -54.99M -53.79M -2.38B
Net Debt 82.74M 59.06M 51.61M 47.62M 43.9M 5.69B 84.58M 569M 224M 2.79B 222M 217M 9.59B 14.06M 10.04M 8.77M 8.1M 7.46M 967M 14.38M 96.76M 38.06M 473M 37.7M 36.88M 1.63B
Logo Conavi Medical Corp.
Conavi Medical Corp. is a Canada-based medical device company. The Company is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. The Novasight Hybrid System is intended for intravascular imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. Its Novasight Hybrid System combines both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. Hybrid IVUS and OCT imaging provides additional information over single modality imaging in complex lesions. The versatility of hybrid imaging is useful for a variety of complex percutaneous coronary interventions (PCIs), including situations where the customer may want to image large ostial lesions with IVUS but also use OCT for diseased distal lesions and/or stent assessment.
Employees
-
Date Price Change Volume
17/07/26 US$0.1579 +0.71% 15,426
15/07/26 US$0.1568 +4.52% 17,158
14/07/26 US$0.1500 -5.36% 6,798
13/07/26 US$0.1585 -6.52% 5,398

Annual profits - Rate of surprise